Insmed (INSM) Receiving Positive Media Coverage, Study Finds
News coverage about Insmed (NASDAQ:INSM) has trended positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a coverage optimism score of 0.29 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.4322902536084 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference (finance.yahoo.com)
- Insmed Sees Unusually Large Options Volume (INSM) (americanbankingnews.com)
- Noteworthy Stocks to Watch for: Insmed Incorporated (NASDAQ:INSM), Nxt-ID, Inc. (NASDAQ:NXTD) – The Oracle Examiner (oracleexaminer.com)
- Hot Stock’s Trend Recap – Insmed Incorporated (NASDAQ: INSM) – Alpha Beta Stock (alphabetastock.com)
Shares of Insmed (NASDAQ:INSM) traded up $0.27 during trading hours on Thursday, hitting $26.52. The company had a trading volume of 45,563 shares, compared to its average volume of 951,329. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1,970.42, a P/E ratio of -8.48 and a beta of 1.09. Insmed has a 1 year low of $11.49 and a 1 year high of $33.94.
In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total transaction of $487,500.00. Following the completion of the sale, the director now directly owns 71,131 shares of the company’s stock, valued at approximately $2,311,757.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.03% of the stock is currently owned by company insiders.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.